CCL Pharmaceuticals (Pvt.) Limited
Private pharmaceutical manufacturer · Lahore · Pakistan
Lahore-headquartered pharmaceutical and healthcare company with manufacturing operations and a multi-country commercial presence.
What is sourced, and how recent is it?
Regulatory-source portfolio data and company-supplied/corporate profile fields are tracked separately. Company claim/verification status is separate from source quality. An unclaimed company can still have a fully official-source-observed portfolio.
Company profile
- Company type
- Private pharmaceutical manufacturer
- Address
- 65, Quaid-e-Azam Industrial Estate, Kot Lakhpat, Lahore, Pakistan
- Website
- cclpharma.com ↗
- Phone
- +92 42 111 225 678
- Official contact
- Contact page ↗
- Official company profile ↗
- Corporate source details checked
- 16 Aug 2026
- Corporate profile completeness
- 88%
Company location
A sourced company location is recorded. Use the map link below for directions.
Portfolio at a glance
RegistrationA unique regulatory registration number. One registration may have more than one strength/form/pack presentation.
PresentationA distinct medicine presentation, such as a particular strength, dosage form and pack.
IndexedA canonical MedInfoBase presentation that passed MedInfoBase identity and publication controls.
Source observedAn additional presentation observed in an official DRAP source but not counted as an indexed MedInfoBase presentation.
Registry onlyAn exact registry-verified registration not otherwise represented by an indexed or source-observed presentation.
Registry verifiedAn exact registration match found in an official DRAP registry source. This is evidence status, not a commercial ranking.
How complete is this profile?
Downloadable company intelligence charts
Copy or download any chart as a presentation-ready PNG. Every exported chart keeps MedInfoBase attribution and the source company-profile URL.
Therapeutic Portfolio Mix
Shows where the company portfolio is concentrated across broad therapeutic areas.
Portfolio distribution, not sales or market-share data.
Dosage Form Portfolio
Shows how the company portfolio is distributed across tablets, capsules, injections, liquids and other forms.
Counts are product presentations, not production or sales volumes.
Equivalent Price Position
Shows whether safely comparable products are below, near or above the peer median unit price.
This is price-position intelligence, not sales, demand or market-share data.
Closest Portfolio Competitors
Highlights other manufacturers with the greatest generic overlap with this company portfolio.
Competitor ranking is based on shared generics in MedInfoBase, not commercial sales performance.
Therapeutic areas
High-level clinical areas represented by this company’s current MedInfoBase portfolio.
Drug classes
More specific classes derived from the canonical generic and preserved curated classifications.
Dosage forms
How MedInfoBase classifies the portfolio
MedInfoBase uses a two-level taxonomy. Therapeutic area is a broad portfolio category, while drug class is the more specific pharmacological or clinical class. Existing curated classifications are preserved. Blank records are assigned conservatively from the canonical generic name and, when available, ATC information. Multi-use medicines may be placed in a cross-therapeutic category rather than forced into a single indication.
Deepest brand families
Unit-price positioning vs equivalent products
How MedInfoBase calculates price position
Only current prices with safely interpretable pack quantities are used. A product is compared only with the same generic, same stated strength, same dosage form and a compatible unit basis such as tablet, capsule, mL or gram. These are database-derived price comparisons, not sales or market-share estimates.
Portfolio overlap
Companies sharing the largest number of generics with this portfolio. This measures product overlap, not commercial performance.
Observed database signals
These dates describe records observed by MedInfoBase. They should not be interpreted as product launch dates or sales activity.
Medicine portfolio
This unified portfolio keeps three evidence lanes distinct: indexed MedInfoBase presentations, additional source-observed presentations, and registry-only registrations that are not otherwise represented. A registration number is not the same thing as a presentation, and source-observed rows are not counted as indexed. Source-only rows with a strength/form/pack contradiction remain visible as evidence but the conflicting field is held for normalization.
| Brand | Generic | Strength | Form | Pack | Registration | Source-listed price | Unit price | Price position |
|---|---|---|---|---|---|---|---|---|
| Hulac liquid | Lactulose | 3.3 g/5 mL | Oral liquid | 120ml | 093177 | PKR 265.47 | PKR 2.21/mL | 6% above median |
| IOCAB | Potassium iodide | 130 mg | Tablet | 20's | 111871 | PKR 75.42 | PKR 3.77/tablet | 46% above median |
| IOCAB | Potassium iodide | 65 mg | Tablet | 20's | 111872 | PKR 40.60 | PKR 2.03/tablet | 6% above median |
| ISOR | Isosorbide dinitrate | 5 mg | Tablet | 100's | 045962 | PKR 64.19 | PKR 0.64/tablet | No comparator |
| ISOR | Isosorbide dinitrate | 10 mg | Tablet | 100's | 045970 | PKR 146.32 | PKR 1.46/tablet | 7% above median |
| ISOR | Isosorbide dinitrate | 20 mg | Tablet | 60's | 057343 | PKR 298.35 | PKR 4.97/tablet | 27% below median |
| JARDY | Empagliflozin | 25 mg | Tablet | 14's | 094003 | PKR 1,529.29 | PKR 109.24/tablet | 10% above median |
| JARDY | Empagliflozin | 10 mg | Tablet | 14's | 094004 | PKR 1,277.68 | PKR 91.26/tablet | 10% above median |
| Jarzem | Empagliflozin | 10 mg | Tablet | 14's | 111969 | PKR 1,411.03 | PKR 100.79/tablet | 22% above median |
| Jarzem | Empagliflozin | 25 mg | Tablet | 14's | 111970 | PKR 1,688.88 | PKR 120.63/tablet | 21% above median |
| LAMITRA | Lamotrigine = | 50 mg | Tablet | 30's | 042693 | PKR 864.89 | PKR 28.83/tablet | Near median |
| LAMITRA | Lamotrigine = | 25 mg | Tablet | 30's | 042694 | PKR 648.65 | PKR 21.62/tablet | Near median |
| LAMITRA | Lamotrigine = | 100 mg | Tablet | 30's | 042695 | PKR 1,081.10 | PKR 36.04/tablet | Near median |
| Lecetam | Levetiracetam | 250 mg | Tablet | 10's | 095453 | PKR 646.07 | PKR 64.61/tablet | 17% above median |
| Lecetam | Levetiracetam | 500 mg | Tablet | 10's | 095454 | PKR 1,072.68 | PKR 107.27/tablet | 13% above median |
| Lecetam | Levetiracetam | 750 mg | Tablet | 10's | 095455 | PKR 1,430.24 | PKR 143.02/tablet | 9% above median |
| LEUCOFOLATE | Calcium folinate (folinic acid) | 15 mg | Injection | 2mlx5's | 093675 | PKR 1,575.79 | PKR 157.58/mL | 8% below median |
| LEUCOFOLATE | Calcium folinate (folinic acid) | 15 mg | Injection | 2mlx1's | 093675 | PKR 342.91 | PKR 171.46/mL | 9% above median |
| LEUCOFOLATE | Calcium folinate (folinic acid) | 50 mg | Injection | 5mlx10's | 093676 | PKR 8,753.07 | PKR 175.06/mL | 8% below median |
| LEUCOFOLATE | Calcium folinate (folinic acid) | 50 mg | Injection | 5mlx1's | 093676 | PKR 951.42 | PKR 190.28/mL | 9% above median |
| LEUCOFOLATE | Calcium folinate (folinic acid) | 100 mg | Injection | 10ml | 093677 | PKR 1,585.69 | PKR 158.57/mL | No comparator |
| Leukozole | Fluconazole | 50 mg | Capsule | 7's | 096600 | PKR 873.66 | PKR 124.81/capsule | Near median |
| Leukozole | Fluconazole | 150 mg | Capsule | 2's | 106311 | PKR 270.12 | PKR 135.06/capsule | 49% below median |
| Leukozole | Fluconazole | 150 mg | Capsule | 1's | 106311 | PKR 135.06 | PKR 135.06/capsule | 49% below median |
| LEVOCIL | Levofloxacin | 250 mg | Tablet | 10's | 023985 | PKR 610.61 | PKR 61.06/tablet | 27% above median |
| LEVOCIL | Levofloxacin | 500 mg | Tablet | 10's | 029542 | PKR 801.42 | PKR 80.14/tablet | Near median |
| LOSIRAL | Letrozole | 2.5 mg | Tablet | 30's | 053873 | PKR 14,593.62 | PKR 486.45/tablet | 21% above median |
| LYMPHOSIDE | Etoposide | 100 mg | Injection | Per vial | 044846 | PKR 1,135.92 | PKR 1,135.92/vial/unit | Near median |
| MALGO | Artemether + Lumefantrine | 20 mg + 120 mg | Tablet | 16's | 042711 | PKR 660.90 | PKR 41.31/tablet | 5% above median |
| MALGO | Artemether | 80 mg | Injection | 6-Amps | 042713 | PKR 1,213.93 | — | No comparator |
| MALGO | Artemether | 80 mg | Injection | 1's | 042713 | PKR 202.32 | PKR 202.32/vial/unit | Near median |
| MALGO | Artemether + Lumefantrine | 40 mg + 240 mg | Tablet | 8's | 054134 | PKR 551.57 | PKR 68.95/tablet | 8% above median |
| MALGO | Artemether | 40 mg | Injection | 1mlx10's | 068118 | PKR 1,253.56 | PKR 125.36/mL | 13% above median |
| MALGO 80/480 | Artemether + Lumefantrine | 80 mg + 480 mg | Tablet | 6's | 057695 | PKR 689.46 | PKR 114.91/tablet | 5% above median |
| MALGO 80/480 | Artemether + Lumefantrine | 80 mg + 480 mg | Tablet | 4's | 057695 | PKR 459.64 | PKR 114.91/tablet | 5% above median |
| MATRIP | Sumatriptan | 25 mg | Tablet | 6's | 042709 | PKR 504.39 | PKR 84.07/tablet | 8% above median |
| MATRIP | Sumatriptan | 25 mg | Tablet | 12's | 042709 | PKR 958.46 | PKR 79.87/tablet | Near median |
| MATRIP | Sumatriptan | 50 mg | Tablet | 6's | 042710 | PKR 752.19 | PKR 125.37/tablet | 10% above median |
| MATRIP | Sumatriptan | 50 mg | Tablet | 12's | 042710 | PKR 1,504.38 | PKR 125.37/tablet | 10% above median |
| MAXIVIR | Lamivudine | 100 mg | Tablet | 14's | 029953 | PKR 1,950.84 | PKR 139.35/tablet | 146% above median |
| MEBREXEL | Docetaxel | 80 mg | Injection | Per vial | 045606 | PKR 31,598.91 | PKR 31,598.91/vial/unit | Near median |
| MEBREXEL | Docetaxel | 20 mg | Injection | Per vial | 045608 | PKR 12,826.25 | PKR 12,826.25/vial/unit | Near median |
| METAPLAXEL | Paclitaxel (albumin-bound nanoparticles) | 30 mg/5 mL | Injection | Per vial | 044850 | PKR 6,122.53 | PKR 6,122.53/vial/unit | 5% above median |
| METAPLAXEL | Paclitaxel | 150 mg/25 mL | Injection | Per vial | 045713 | PKR 25,196.71 | PKR 25,196.71/vial/unit | No comparator |
| METOMIDESource observed | Metoclopramide | 5 mg | Held for normalizationSource reported: Tablet · structural field conflict | 20 ml | 002811Official source ↗ | No indexed price | — | — |
| METOMIDESource observed | Metoclopramide | 5 mg/5 mL | Held for normalizationSource reported: Tablet · structural field conflict | 50 ml | 002811Official source ↗ | No indexed price | — | — |
| METOMIDE | Metoclopramide | 10 mg | Tablet | 20's | 002812 | PKR 20.89 | PKR 1.04/tablet | 54% below median |
| METOMIDE | Metoclopramide | 10 mg | Tablet | 100's | 002812 | PKR 267.40 | PKR 2.67/tablet | 26% above median |
| METOMIDE | Metoclopramide | 10 mg/2 mL | Injection | 10 Amp | 010152 | PKR 413.06 | PKR 41.31/vial/unit | Near median |
| MOLOX | Moxifloxacin | 400 mg | Tablet | 5's | 042716 | PKR 994.57 | PKR 198.91/tablet | 8% above median |
MedInfoBase company-intelligence methodology
This page is generated from MedInfoBase medicine, generic, company, price and official-source records. Unverified third-party discovery records are retained internally for coverage auditing and are not published as company registrations. Portfolio leaders are ranked by presentation depth, not sales. Price-position metrics are calculated from current official-source prices normalized to compatible units and compared only against like-for-like products with the same generic, stated strength and dosage form.
Not currently included: sales volume, revenue by brand, market share, prescription volume or best-selling rankings. MedInfoBase will display those only when supported by a defensible licensed, public or company-verified source.
Cite this record
Manufacturer recordRecords change over time. Please cite the access date so readers can locate the version you used.